Boston Scientific Q2 results beat estimates on cardiovascular strength 

Overview

• Medical device maker's Q2 revenue grew 7.5% yr/yr, beating analyst expectations

• Adjusted EPS for Q2 rose to $0.86, beating analyst expectations

• Company completed $2 bln accelerated share repurchase program

Outlook

• Boston Scientific sees full-year 2026 net sales growth of 5.5% to 6.5% reported

• Company expects full-year 2026 adjusted EPS of $3.28 to $3.32

• Boston Scientific sees Q3 2026 net sales growth of 3% to 5% reported and organic

Result Drivers

• CARDIOVASCULAR GROWTH - Cardiovascular segment sales rose 8.3% yr/yr on a reported basis and 7.8% operationally, contributing to overall revenue growth

• STRONG EMERGING MARKETS - Asia-Pacific sales grew 11.2% and Latin America/Canada sales rose 22.4% yr/yr, supporting overall company growth

• INNOVATION AND CLINICAL MILESTONES - Co cited investments in innovation and positive clinical trial results as supporting its growth strategy

Company press release: ID:nPn9hf8dha

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 28 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment technology peer group is "buy"

• Wall Street's median 12-month price target for Boston Scientific Corp is $70.00, about 52% above its July 28 closing price of $46.06

• The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads

• July 27 - Boston Scientific unveils new restructuring plan, expects job cuts

• July 29 - Integra LifeSciences Q2 revenue slightly beats, adjusted EPS tops estimates

• July 28 - UK's Creo Medical H1 revenue rises 45%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)